How to treat hypertension in diabetic patients

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The coexistence of hypertension in a patient with diabetes presents a therapeutic challenge. Attempts to favorably influence cardiovascular risk factors related to atherosclerosis - stroke, cardiac failure, peripheral arterial disease, and coronary artery disease - are confounded by the metabolic effects of diabetes and its renal complications. Early identification of patients at risk for diabetic nephropathy and initiation of antihypertensive treatment may markedly improve morbidity and mortality in these patients. Antihypertensive drugs for patients with diabetes should be chosen carefully. Although most are effective, many have metabolic effects that can offset much of the benefit of lowered blood pressure. Of particular concern with thiazide diuretics and beta-adrenergic blocking agents are their effects on glycemic control and lipid status, two major atherogenic risk factors. Other antihypertensive drugs have characteristics that may adversely impact the patient's quality of life. Angiotensin converting enzyme (ACE) inhibitors, calcium-entry blockers, and alpha1-adrenergic blocking agents effectively reduce blood pressure and have little impact on insulin secretion and glycemic control. These agents do not adversely influence subclinical autonomic neuropathy, nor do they increase cardiovascular risk factors by elevating atherogenic lipid components. Independent of these effects, preliminary findings in hypertensive diabetic patients with nephropathy suggest that renal function may be protected through the action of ACE inhibition on intrarenal hemodynamics.

Original languageEnglish (US)
Pages (from-to)213-216+225
JournalPostgraduate Medicine
Volume83
Issue number2
StatePublished - 1988

Fingerprint

Hypertension
Antihypertensive Agents
Blood Pressure
Sodium Chloride Symporter Inhibitors
Kidney
Lipids
Adrenergic beta-Antagonists
Adrenergic Antagonists
Peripheral Arterial Disease
Diabetic Nephropathies
Peptidyl-Dipeptidase A
Angiotensin-Converting Enzyme Inhibitors
Coronary Artery Disease
Atherosclerosis
Heart Failure
Hemodynamics
Stroke
Quality of Life
Insulin
Calcium

ASJC Scopus subject areas

  • Medicine(all)

Cite this

How to treat hypertension in diabetic patients. / Raskin, Philip.

In: Postgraduate Medicine, Vol. 83, No. 2, 1988, p. 213-216+225.

Research output: Contribution to journalArticle

@article{f65bd62877ab4e06a349d7c2997f93e0,
title = "How to treat hypertension in diabetic patients",
abstract = "The coexistence of hypertension in a patient with diabetes presents a therapeutic challenge. Attempts to favorably influence cardiovascular risk factors related to atherosclerosis - stroke, cardiac failure, peripheral arterial disease, and coronary artery disease - are confounded by the metabolic effects of diabetes and its renal complications. Early identification of patients at risk for diabetic nephropathy and initiation of antihypertensive treatment may markedly improve morbidity and mortality in these patients. Antihypertensive drugs for patients with diabetes should be chosen carefully. Although most are effective, many have metabolic effects that can offset much of the benefit of lowered blood pressure. Of particular concern with thiazide diuretics and beta-adrenergic blocking agents are their effects on glycemic control and lipid status, two major atherogenic risk factors. Other antihypertensive drugs have characteristics that may adversely impact the patient's quality of life. Angiotensin converting enzyme (ACE) inhibitors, calcium-entry blockers, and alpha1-adrenergic blocking agents effectively reduce blood pressure and have little impact on insulin secretion and glycemic control. These agents do not adversely influence subclinical autonomic neuropathy, nor do they increase cardiovascular risk factors by elevating atherogenic lipid components. Independent of these effects, preliminary findings in hypertensive diabetic patients with nephropathy suggest that renal function may be protected through the action of ACE inhibition on intrarenal hemodynamics.",
author = "Philip Raskin",
year = "1988",
language = "English (US)",
volume = "83",
pages = "213--216+225",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "2",

}

TY - JOUR

T1 - How to treat hypertension in diabetic patients

AU - Raskin, Philip

PY - 1988

Y1 - 1988

N2 - The coexistence of hypertension in a patient with diabetes presents a therapeutic challenge. Attempts to favorably influence cardiovascular risk factors related to atherosclerosis - stroke, cardiac failure, peripheral arterial disease, and coronary artery disease - are confounded by the metabolic effects of diabetes and its renal complications. Early identification of patients at risk for diabetic nephropathy and initiation of antihypertensive treatment may markedly improve morbidity and mortality in these patients. Antihypertensive drugs for patients with diabetes should be chosen carefully. Although most are effective, many have metabolic effects that can offset much of the benefit of lowered blood pressure. Of particular concern with thiazide diuretics and beta-adrenergic blocking agents are their effects on glycemic control and lipid status, two major atherogenic risk factors. Other antihypertensive drugs have characteristics that may adversely impact the patient's quality of life. Angiotensin converting enzyme (ACE) inhibitors, calcium-entry blockers, and alpha1-adrenergic blocking agents effectively reduce blood pressure and have little impact on insulin secretion and glycemic control. These agents do not adversely influence subclinical autonomic neuropathy, nor do they increase cardiovascular risk factors by elevating atherogenic lipid components. Independent of these effects, preliminary findings in hypertensive diabetic patients with nephropathy suggest that renal function may be protected through the action of ACE inhibition on intrarenal hemodynamics.

AB - The coexistence of hypertension in a patient with diabetes presents a therapeutic challenge. Attempts to favorably influence cardiovascular risk factors related to atherosclerosis - stroke, cardiac failure, peripheral arterial disease, and coronary artery disease - are confounded by the metabolic effects of diabetes and its renal complications. Early identification of patients at risk for diabetic nephropathy and initiation of antihypertensive treatment may markedly improve morbidity and mortality in these patients. Antihypertensive drugs for patients with diabetes should be chosen carefully. Although most are effective, many have metabolic effects that can offset much of the benefit of lowered blood pressure. Of particular concern with thiazide diuretics and beta-adrenergic blocking agents are their effects on glycemic control and lipid status, two major atherogenic risk factors. Other antihypertensive drugs have characteristics that may adversely impact the patient's quality of life. Angiotensin converting enzyme (ACE) inhibitors, calcium-entry blockers, and alpha1-adrenergic blocking agents effectively reduce blood pressure and have little impact on insulin secretion and glycemic control. These agents do not adversely influence subclinical autonomic neuropathy, nor do they increase cardiovascular risk factors by elevating atherogenic lipid components. Independent of these effects, preliminary findings in hypertensive diabetic patients with nephropathy suggest that renal function may be protected through the action of ACE inhibition on intrarenal hemodynamics.

UR - http://www.scopus.com/inward/record.url?scp=0023857492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023857492&partnerID=8YFLogxK

M3 - Article

C2 - 2893365

AN - SCOPUS:0023857492

VL - 83

SP - 213-216+225

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 2

ER -